title: Ghrelin and cachexia: will treatment with GHSR-1a agonists make a difference for patients suffering from chronic wasting syndromes?
abstract: Cachexia is a syndrome of wasting and anorexia that worsens the prognosis of many chronic diseases including cancer, chronic kidney disease, chronic heart disease and chronic obstructive pulmonary disease. Properties of the orexigenic hormone ghrelin-including appetite-stimulation, weight-gain production and increased cardiac output make it a logical treatment for cachexia. While endogenous ghrelin levels are increased in the setting of cachexia, treatment with ghrelin and other GHSR-1a agonists in animal models of cachexia and in humans with cachexia has demonstrated consistent effects of increased appetite and improved weight gain. These positive effects occur in multiple underlying diseases associated with cachexia and appear to be sustained over treatment duration of up to 12 weeks. The mechanism of action in producing these effects is likely related to stimulation of central appetite centers such as the central melanocortin system and to increased growth hormone release, though ghrelin's effects may also relate to decreased systemic inflammation and other direct and indirect actions. Questions regarding the long-term safety of ghrelin treatment are still unanswered, as is the important question of whether successful treatment of cachexia will improve the prognosis of the underlying disease itself.
authors.affiliation: Department of Pediatrics, University of Virginia School of Medicine, Charlottesville, VA 22908, USA. deboer@virginia.edu
authors.forename: Mark D
authors.initials: MD
authors.lastname: DeBoer
mesh_terms: D002100:Cachexia / Q000188:drug therapy* / Q000378:metabolism*; D002908:Chronic Disease; D054439:Ghrelin / Q000378:metabolism*; D006801:Humans; D008954:Models, Biological; D054440:Receptors, Ghrelin / Q000819:agonists*; D019282:Wasting Syndrome / Q000188:drug therapy*
chemical_list: D054439:Ghrelin; D054440:Receptors, Ghrelin